Medicina, Vol. 56 No. 1, 2020.
Izvorni znanstveni članak
https://doi.org/10.21860/medflum2020_232817
Comparison of efficacy and three year retention rate of TNF-α inhibitors in treatment of ankylosing spondylitis
Filip Mirić
orcid.org/0000-0001-6053-1469
; Klinika za internu medicinu, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Srđan Novak
; Klinika za internu medicinu, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Sažetak
Aim: Our goal was to compare efficacy and retention rate of TNF-α (tumor necrosis factor-α) inhibitors (adalimumab, golimumab, infliximab) during three-year follow-up in treatment of ankylosing spondylitis. Materials and methods: This retrospective study includes 29 patients who received first biological drug at Department of Rheumatology at Clinical Hospital Center Rijeka. They started with biological drug in the period from 1/2009-6/2015 and were followed for three years after the onset of therapy. Disease activity was measured with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), BASFI (Bath Ankylosing Spondylitis Functional Index), CRP (C reactive protein) and VAS (Visual Analogue Scale) on week 0, then 3 and 36 months after first therapy. Results: Among 29 patients 11 were on adalimumab, 10 on golimumab, and 8 on infliximab. By analyzing the parameters included in this study (BASDAI, BASFI, CRP, VAS) and considering the TNF-α inhibitor which has been used, there is no statistically significant difference in any observed period (all p values>0,05). Overall 3 years retention rate for TNF-α inhibitors was 75,8 %. In patients treated with adalimumab 3 years retention rate was 72,8 %, for golimumab was 80 % and for infliximab 75 % (all p values>0,05). Conclusions: Comparing patients treated with adalimumab, golimumab and infliximab as first line of biological therapy, our study on small number of patients has shown that there is no significant difference in their efficacy and retention rate.
Ključne riječi
adalimumab; ankylosing spondylitis; golimumab; infliximab; TNF-α inhibitor
Hrčak ID:
232817
URI
Datum izdavanja:
1.3.2020.
Posjeta: 1.646 *